Agenda-8-27-21
The Live Virtual Experience will include top experts sharing highlights from over 25 on-demand presentations*, available 9 September 2021. The on-demand presentations will be available through the virtual platform. These interactive panel discussions will also feature debates and Q&A from the live audience.
= On-Demand Presentation
= Live Presentation** = Oral Presenation
Friday 17 September 2021
Day 1
| 9:00 AM (EDT) 15:00 (CEST) |
5 mins | Opening Remarks |
Tadeusz Robak, MD, PhD |
| Theme 1: Pathogenesis of CLL | |||
| 9:05 AM (EDT) 15:05 (CEST) |
5 mins | Session 1: Molecular Pathogenesis of CLL – Genomics and Proteomics |
Co-Chairs: Catherine J. Wu, MD & Clare Sun, MD |
| Genomic Analysis of CLL On-Demand Presentation |
Anna Schuh, MD, PhD | ||
| Novel Insights From Proteogenomic Analysis On-Demand Presentation |
Michael Gillette, MD, PhD | ||
| 9:10 AM (EDT) 15:10 (CEST) |
30 mins | Panel Discussion featuring highlights from the following on-demand presentations: *Genomic Analysis of CLL & *Novel Insights From Proteogenomic Analysis |
Catherine J. Wu, MD; Clare Sun, MD; Anna Schuh, MD, PhD; Michael Gillette, MD, PhD |
| 9:40 AM (EDT) 15:40 (CEST) |
10 mins | **Effects of SF3B1 K700E mutation in chronic lymphocytic leukemia and the opportunity for targeted therapy with SF3B1-binding splicing modulator H3B-8800 (1084295) |
Irene Lopez-Oreja, PhD |
| 9:50 AM (EDT) 15:50 (CEST) |
10 mins | **Patterns of BTK Mutation and Clonal Evolution Induced by the Selective BTK Inhibitor (BTKi), Tirabrutinib in Chronic Lymphocytic Leukaemia (CLL) (1083945) |
Ross Jackson, PhD |
| 10:00 AM (EDT) 16:00 (CEST) |
5 mins | Visit Exhibit Hall & Break | |
| 10:05 AM (EDT) 16:05 (CEST) |
5 mins | Session 2: Molecular Pathogenesis of CLL – Microenvironment & Signaling |
Co-Chairs: Nicholas Chiorazzi, MD & Sarka Pospisilova, PhD |
|
Trafficking of CLL Cells To and From the Microenvironmental Niche
|
Andrea Pepper, PhD | ||
| Effects of Distinct Receptor-Ligand Systems (BCR, TLR, Chemokine Receptors) in the Survival and Growth of CLL Cells On-Demand Presentation |
Dimitar Efremov, MD, PhD | ||
| Crosstalk of Microenvironmental Elements in the Tissue Microenvironment On-Demand Presentation |
Alan Ramsay, PhD | ||
| 10:10 AM (EDT) 16:10 (CEST) |
36 mins | Panel Discussion featuring highlights from the following on-demand presentations: *Trafficking of CLL Cells To and From the Microenvironmental Niche *Effects of Distinct Receptor-Ligand Systems (BCR, TLR, Chemokine Receptors) in the Survival and Growth of CLL Cells *Crosstalk of Microenvironment Elements in the Tissue Microenvironment |
Nicholas Chiorazzi, MD; Sarka Pospisilova, PhD; Andrea Pepper, PhD; Dimitar Efremov, MD, PhD; Alan Ramsay, PhD |
| 10:46 AM (EDT) 16:46 (CEST) |
7 mins | **Adaptation of Chronic Lymphocytic Leukemia to Ibrutinib Is Mediated by Epigenetic Plasticity of Residual Disease and By-pass Signaling via MAPK Pathway (1084084) |
Lodovico Terzi di Bergamo, MSc |
| 10:53 AM (EDT) 16:53 (CEST) |
7 mins | **GAB1 – Novel Regulator of Migration Capacity and Tonic AKT Activity in CLL: Implications for Combinatorial Therapy with BCR Inhibitors (1084081) |
Vaclav Seda, MSc |
| 11:00 AM (EDT) 17:00 (CEST) |
5 mins | Visit Exhibit Hall & Break | |
| 11:05 AM (EDT) 17:05 (CEST) |
5 mins | Session 3: Clonal Dynamics, Competition, and Disease Evolution |
Co-Chairs: Gianluca Gaidano, MD, PhD & Adalgisa Condoluci, MD |
| Mechanisms of Epigenetic Dynamics/Evolution On-Demand Presentation |
Davide Rossi, MD, PhD | ||
| Perspectives of Clonal Evolution at the Single-Cell Level On-Demand Presentation |
Catherine J. Wu, MD | ||
| 11:10 AM (EDT) 17:10 (CEST) |
10 mins | **Single-cell Dynamics of Mitochondrial DNA Mutations and Chromatin Accessibility in Chronic Lymphocytic Leukemia Following Therapeutic Bottlenecks (1084075) |
Livius Penter, MD |
| 11:20 AM (EDT) 17:20 (CEST) |
10 mins | **Venetoclax resistance mechanisms in CLL identified by whole exome and RNA sequencing on longitudinal patient samples (1084402) |
Jasneet K. Khalsa, PhD |
| 11:30 AM (EDT) 17:30 (CEST) |
30 mins | Panel Discussion featuring highlights from the following on-demand presentations: *Mechanisms of Epigenetic Dynamics/Evolution *Perspectives of Clonal Evolution at the Single-Cell Level |
Gianluca Gaidano, MD, PhD; Adalgisa Condoluci, MD; Davide Rossi, MD, PhD; Catherine J. Wu, MD |
| 12:00 PM (EDT) 18:00 (CEST) |
End of Day 1 | ||
| 12:00 PM (EDT) 18:00 (CEST) |
60 mins | Poster Session |
|
| 12:00 PM (EDT) 18:00 (CEST) |
Establishment and Molecular Characterization of a 3D Bioprinted Chronic Lymphocytic Leukemia (CLL) in Vitro Model (1083882) |
Riccardo Pinos, MSc | |
| 12:05 PM (EDT) 18:05 (CEST) |
Ibrutinib Blocks CD40 Signaling in CLL in Vivo by Reducing TRAF4 Levels (1084082) |
Sonali Sharma, PhD | |
| 12:10 PM (EDT) 18:10 (CEST) |
Role of Ahr and Hif1a in the Suppressive Ability of Tregs During CLL Development (1083804) |
Giulia Maria Pagano, MSc | |
| 12:15 PM (EDT) 18:15 (CEST) |
Single-cell RNA Sequencing Suggests Novel Drivers of Chronic Lymphocytic Leukemia in Patients with Ibrutinib Resistance (1084066) |
Hui Jin, MD | |
| 12:20 PM (EDT) 18:20 (CEST) |
Analysis of BTK-independent Calcium Signaling Downstream of the B-cell Receptor Signaling in Human Malignant B Cells (1083841) |
Beatriz Valle-Argos, PhD | |
| 12:25 PM (EDT) 18:25 (CEST) |
Detection of Rare Germline Variants in the Genomes of Patients with B-Cell Neoplasms (1084074) |
Adrián Mosquera Orgueira, MD | |
| 12:30 PM (EDT) 18:30 (CEST) |
GEUS-CLL: a comprehensive assay that integrates (epi)genetic information with clinical impact in CLL (1084248) |
Ester Cuenca-Leon, PhD | |
| 12:35 PM (EDT) 18:35 (CEST) |
IL4-STAT6 Signaling Induces CD20 in Chronic Lymphocytic Leukemia and This Axis Is Repressed by PI3Kδ Inhibitor Idelalisib (1084080) |
Marek Mraz, MD, PhD | |
| 12:40 PM (EDT) 18:40 (CEST) |
Discussion | ||
| 1:00 PM (EDT) 19:00 (CEST) |
Poster Session Concludes |
Saturday 18 September 2021
Day 2
| Theme 2: Approach Considerations and Treatment Options in CLL | |||
| 9:00 AM (EDT) 15:00 (CEST) |
5 mins | Opening Remarks & Recap of Previous Day |
Kostas Stamatopoulos, MD, PhD |
| 9:05 AM (EDT) 15:05 (CEST) |
5 mins | Session 4: Prognostication and Prediction in the Era of Novel Drugs |
Chair: Peter Hillmen, MB ChB, PhD & Carol Moreno, MD, PhD |
| The Use of Conventional Prognostic Markers with Targeted Therapy On-Demand Presentation |
Eugen Tausch, MD | ||
| Genomic Profiling and Treatment Decisions in the Non-Chemotherapy Era On-Demand Presentation |
Romain Guièze, MD | ||
| 9:10 AM (EDT) 15:10 (CEST) |
45 mins | Panel Discussion featuring highlights from the following on-demand presentations: *The Use of Conventional Prognostic Markers with Targeted Therapy *Genomic Profiling and Treatment Decisions in the Non-Chemotherapy Era |
Peter Hillmen, MB ChB, PhD; Eugen Tausch, MD; Romain Guièze, MD; Carol Moreno, MD, PhD |
| 9:55 AM (EDT) 15:55 (CEST) |
10 mins | **Integration of pre-, on- and post-treatment risk factors, including CLL-IPI and MRD, improves outcome prediction after fixed-duration therapy of CLL: Introduction of the refined Continuous Individualized Risk Index (CIRI2-CLL) (1084256) |
Othman Al-Sawaf, MD |
| 10:05 AM (EDT) 16:05 (CEST) |
10 mins | **The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI), a Disease-specific Comorbidity Scale Validated in Two Independent Cohorts (1083230) |
Max J. Gordon, MD |
| 10:15AM (EDT) 16:15 (CEST) |
5 mins | Visit Exhibit Hall & Break | |
| 10:20 AM (EDT) 16:20 (CEST) |
5 mins | Session 5: Minimal Residual Disease – Methods and Clinical Application |
Co-Chairs: Thomas Kipps, MD, PhD & Kirsten Fischer, MD |
| Minimal Residual Disease On-Demand Presentation |
William Wierda, MD, PhD | ||
| 10:25 AM (EDT) 16:25 (CEST) |
20 mins | Debate: To MRD or Not to MRD – Can We Use MRD to Direct Standard Practice? |
Moderator: Thomas Kipps, MD, PhD Debaters: |
| 10:45 AM (EDT) 16:45 (CEST) |
25 mins | Panel Discussion featuring highlights from the following on-demand presentations: *Minimal Residual Disease |
Thomas Kipps, MD, PhD; Kirsten Fischer, MD; William Wierda, MD, PhD |
| 11:10 AM (EDT) 17:10 (CEST) |
10 mins | **Cell-free DNA (cfDNA)-based Serial Minimal Residual Disease Assessment in Patients with Chronic Lymphocytic Leukemia Treated with Time-limited Obinutuzumab, Acalabrutinib and Venetoclax (1084129) |
Moritz Fürstenau, MD |
| 11:20 AM (EDT) 17:20 (CEST) |
10 mins | **MRD dynamics of patients receiving ibrutinib plus venetoclax in the Blood Cancer UK TAP CLARITY study (1084344) |
Talha Munir, MBBS, MRCP, FRCPath |
| 11:30 AM (EDT) 17:30 (CEST) |
5 mins | Visit Exhibit Hall & Break | |
| 11:35 AM (EDT) 17:35 (CEST) |
60 mins | Industry Supported Symposia | |
| 12:35 PM (EDT) 18:35 (CEST) |
10 mins | Binet/Rai Medal Presentation |
|
| 12:45 PM (EDT) 18:45 (CEST) |
5 mins | Session 6: Front-Line Therapy of CLL |
Co-Chairs: Barbara Eichhorst, MD & Lydia Scarfo, MD |
| Relevant Factors for Choice of Frontline Therapy On-Demand Presentation |
Arnon Kater, MD, PhD | ||
| Treatment of Very High Risk CLL (TP53, Complex Karyotype; IGHV Subset 2) On-Demand Presentation |
Inhye Ahn, MD | ||
| Chemotherapy in the Front Line Setting: Is it Still Useful in Combination with Newer Substances? On-Demand Presentation |
Matthew Davids, MD, MMSc | ||
| 12:50 PM (EDT) 18:50 (CEST) |
30 mins | Panel Discussion featuring highlights from the following on-demand presentations: *Relevant Factors for Choice of Frontline Therapy *Treatment of Very High Risk CLL (TP53, Complex Karyotype; IGHV Subset 2) *Chemotherapy in the Front Line Setting: Is it Still Useful in Combination with Newer Substances? |
Barbara Eichhorst, MD; Lydia Scarfo, MD; Arnon Kater, MD, PhD; Inhye Ahn, MD; Matthew Davids, MD, MMSc |
| 1:20 PM (EDT) 19:20 (CEST) |
10 mins | **Fixed-duration (FD) first-line treatment with ibrutinib plus venetoclax for chronic lymphocytic leukemia/small lymphocytic lymphoma: primary analysis of the FD Cohort of the Phase 2 CAPTIVATE Study (1084132) |
William G. Wierda, MD, PhD |
| 1:30 PM (EDT) 19:30 (CEST) |
10 mins | **Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment-Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 Unity-CLL Study (1083667) |
Wojciech Jurczak, MD, PhD |
| 1:40 PM (EDT) 19:40 (CEST) |
End of Day 2 | ||
| 1:40 PM (EDT) 19:40 (CEST) |
60 mins | Poster Session |
|
| 1:40 PM (EDT) 19:40 (CEST) |
Venetoclax Ramp-Up Strategies For CLL. UK Real World Multicentre Retrospective Study (1084425) |
Rocío Figueroa | |
| 1:45 PM (EDT) 19:45 (CEST) |
Ibrutinib Followed by Ofatumumab Consolidation in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): GELLC-7 Trial from the Spanish Group of CLL (GELLC) (1083359) |
Pau Abrisqueta, MD | |
| 1:50 PM (EDT) 19:50 (CEST) |
Preliminary Results of the FILO Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) versus FCR (1084072) |
Anne-Sophie Michallet | |
| 1:55 PM (EDT) 19:55 (CEST) |
Utilizing serial Minimal Residual Disease (MRD) assessments: Long-term outcomes and insights from modeling MRD growth by Next-Generation Sequencing (NGS) within the randomized CLL14 study evaluating fixed-duration therapy with venetoclax and obinutuzumab (1083240) |
Othman Al-Sawaf, MD | |
| 2:00 PM (EDT) 20:00 (CEST) |
The Impact of COVID-19 on UK CLL Patients (1084086) |
Renata Walewska, MB ChB PhD | |
| 2:05 PM (EDT) 20:05 (CEST) |
Mono-therapy of ibrutinib effectively reduced the incidence of Richter transformation in secondary but not primary lymphoid organs and failed in treating transformed lymphoma in pre-clinical mouse models (1084604) |
Shih-Shih Chen, PhD | |
| 2:10 PM (EDT) 20:10 (CEST) |
Outcomes beyond progression in ibrutinib-treated patients with chronic lymphocytic leukemia (1084582) |
Paul J. Hampel, MD | |
| 2:15PM (EDT) 20:15 (CEST) |
Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Sequentially Resistant to Both BCL2 and BTK Inhibition (1083790) |
Victor S. Lin, MD | |
| 2:20 PM (EDT) 20:20 (CEST) |
Discussion | ||
| 2:40 PM (EDT) 20:40 (CEST) |
Poster Session Concludes |
Sunday 19 September 2021
Day 3
| 7:45 AM (EDT) 13:45 (CEST) |
60 mins | Industry Supported Symposium | |
| 9:00 AM (EDT) 15:00 (CEST) |
5 mins | Opening Remarks & Recap of Previous Day |
Jan Burger, MD, PhD |
| 9:05 AM (EDT) 15:05 (CEST) |
5 mins | Session 7: Treatment of Relapsed/Refractory CLL |
Co-Chairs: John Seymour, MD & Meghan Thompson, MD |
| Resistance to Venetoclax: Mechanisms, Risk Factors and Preventative Strategies On-Demand Presentation |
Andrew Roberts, MBBS, PhD | ||
| A Clinical Perspective on Resistance to Covalent BTKi On-Demand Presentation |
Jennifer Woyach, MD | ||
| Using Genomics and Biologic Profiling to Select the Preferred Targeted Agent for Each Patient On-Demand Presentation |
Richard Rosenquist, MD, PhD | ||
| 9:10 AM (EDT) 15:10 (CEST) |
30 mins | Panel Discussion featuring highlights from the following on-demand presentations: *Resistance to Venetoclax: Mechanisms, Risk Factors, and Preventative Strategies *A Clinical Perspective on Resistance to Covalent BTKi *Using Genomics and Biologic Profiling to Select the Preferred Targeted Agent for Each Patient |
John Seymour, MD; Meghan Thompson, MD; Andrew Roberts, MBBS, PhD; Jennifer Woyach, MD; Richard Rosenquist, MD, PhD |
| 9:40 AM (EDT) 15:40 (CEST) |
10 mins | **Efficacy and Safety of Acalabrutinib versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of a Phase 3 Clinical Trial (1083838) |
Peter Hillmen, MB ChB, PhD |
| 9:50 AM (EDT) 15:50 (CEST) |
10 mins | **First Interim Analysis of ALPINE Study: Results of a Phase 3 Randomized Study of Zanubrutinib vs Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (1084141) |
Peter Hillmen, MB ChB, PhD |
| 10:00AM (EDT) 16:00 (CEST) |
5 mins | Visit Exhibit Hall & Break | |
| Theme 3: Rationally Designed Therapy on the Horizon in CLL | |||
| 10:05 AM (EDT) 16:05 (CEST) |
5 mins | Session 8: New Agents in CLL Clinical Trials |
Co-Chairs: Jennifer Woyach, MD & Lindsey Roeker, MD |
| Refining our Standard Approaches On-Demand Presentation |
Paolo Ghia, MD, PhD | ||
| Reversible BTK Inhibitors On-Demand Presentation |
Jennifer Brown, MD, PhD | ||
| Preclinical Methods for Drug Discovery On-Demand Presentation |
Rosa Lapalombella, PhD | ||
| 10:10 AM (EDT) 16:10 (CEST) |
30 mins | Panel Discussion featuring highlights from the following on-demand presentations: *Refining our Standard Approaches *Reversible BTK Inhibitors *Preclinical Methods for Drug Discovery |
Jennifer Woyach, MD; Lindsey Roeker, MD; Paolo Ghia, MD, PhD; Jennifer Brown, MD, PhD; Rosa Lapalombella, PhD |
| 10:40 AM (EDT) 16:40 (CEST) |
10 mins | **Pirtobrutinib (LOXO-305), a Next Generation, Highly Selective, Non-covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study (1084067) |
Wojciech Jurczak, MD, PhD |
| 10:50 AM (EDT) 16:50 (CEST) |
10 mins | **A Phase 1/2 Study of Umbralisib, Ublituximab, and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) (1083987) |
Paul M. M. Barr, MD |
| 11:00 AM (EDT) 17:00 (CEST) |
60 mins | Industry Supported Symposia |
|
| 12:00 AM (EDT) 18:00 (CEST) |
5 mins | Visit Exhibit Hall & Break | |
| 12:05 PM (EDT) 18:05 (CEST) |
5 mins | Session 9: Immunotherapy of CLL |
Co-Chairs: John Gribben, MD, DSc & David Maloney, MD, PhD |
| 12:10 PM (EDT) 18:10 (CEST) |
30 mins | Debate – CAR T-cell Therapy vs Allo-SCT |
Moderators: John Gribben, MD, DSc; Debaters: |
| T Cells in CLL Biology and Treatment: Friends or Foe? On-Demand Presentation |
Jan Burger, MD, PhD | ||
| Bispecific Monoclonal Antibodies On-Demand Presentation |
Adrian Wiestner, MD, PhD | ||
| 12:40 PM (EDT) 18:40 (CEST) |
12 mins | **TRANSCEND CLL 004: Phase 1 Cohort of Lisocabtagene Maraleucel (Liso-cel) Combined with Ibrutinib for Patients with Relapsed/Refractory CLL/SLL (1084088) |
William G. Wierda, MD, PhD |
| 12:52 PM (EDT) 18:52 (CEST) |
12 mins | **CD19 promoter hypermethylation as means of antigen-negative escape to CART-19 therapy (1084273) |
Lenka Dostalova |
| 1:05 PM (EDT) 19:05 (CEST) |
25 mins | Panel Discussion featuring the following on-demand presentations: *Bispecific Monoclonal Antibodies *T Cells in CLL Biology and Treatment: Friends or Foe? |
John Gribben, MD, DSc David Maloney, MD, PhD Jan Burger, MD, PhD Adrian Wiestner, MD, PhD Jordan Gauthier MD, MSc Peter Dreger, MD |
| 1:30 PM (EDT) 19:30 (CEST) |
End of Day 3 | ||
| 1:30 PM (EDT) 19:30 (CEST) |
60 mins | Poster Session |
|
| 1:30 PM (EDT) 19:30 (CEST) |
Longer term follow-up of a multicenter, phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, rituximab (iFCR) as initial therapy for younger patients with chronic lymphocytic leukemia (1084315) |
Matthew S. Davids, MD, MMSc | |
| 1:35 PM (EDT) 19:35 (CEST) |
A Phase I Trial of Nedd8-Activating Enzyme (NAE) Inhibitor, Pevonedistat (PEVO) in Combination with Ibrutinib in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin Lymphoma (NHL) (1082565) |
Pallawi Torka, MD | |
| 1:40 PM (EDT) 19:40 (CEST) |
Chronic lymphocytic leukemia actively induces T-cell dysfunction by contact-dependent signaling (1084598) |
J.A.C. van Bruggen | |
| 1:45 PM (EDT) 19:45 (CEST) |
Pirtobrutinib (LOXO-305), A Next Generation, Highly Selective, Non-covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study (1084540) |
Wojciech Jurczak, MD, PhD | |
| 1:50 PM (EDT) 19:50 (CEST) |
BTK inhibitors, irrespective of ITK inhibition, downregulate an immunosuppressive program in chronic lymphocytic leukemia and enhance CD19/CD3-mediated cytotoxicity of T cells (1084197) |
Maissa Mhibik, PhD | |
| 1:55 PM (EDT) 19:55 (CEST) |
First-in-human Study of Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor, in Patients with Relapsed/refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Other Hematologic Malignancies (HMs) (1082531) |
Sikander Ailawadhi, MD | |
| 2:00 PM (EDT) 20:00 (CEST) |
G-1701, a Selective Bruton Tyrosine Kinase (BTK) Inhibitor, as Monotherapy and in Combination with Ublituximab and Umbralisib (U2) in Patients with Chronic Lymphocytic Leukemia (1083634) |
Chan Y. Cheah, MBBS, DMSc | |
| 2:05 PM (EDT) 20:05 (CEST) |
Dual Variable Domain Antibodies Against FcμR for Potential Treatment of Chronic Lymphocytic Leukemia (1083985) |
Amro A. Fulfulan, MS | |
| 2:10 PM (EDT) 20:10 (CEST) |
Discussion | ||
| 2:30 PM (EDT) 20:30 (CEST) |
Poster Session Concludes |
Monday 20 September 2021
Day 4
| 9:00 AM (EDT) 15:00 (CEST) |
5 mins | Opening Remarks & Recap of Previous Day |
Tamar Tadmor, MD |
| 9:05 AM (EDT) 15:05 (CEST) |
5 mins | Session 10: Supportive Care and Consequences of Immune Dysregulation in CLL |
Co-Chairs: Jennifer Brown, MD, PhD; & Jackie Barrientos, MD |
| Infection Risk in CLL On-Demand Presentation |
Carsten Niemann, MD, PhD |
||
| Infection Risk with Novel Agents On-Demand Presentation |
Florence Cymbalista, MD, PhD |
||
| COVID-19 and CLL On-Demand Presentation |
Lydia Scarfò, MD |
||
| Management of Autoimmune Cytopenias in the Era of Targeted Agents On-Demand Presentation |
Kerry Rogers, MD |
||
| Management of Cardiac Complications of BTK Inhibitors On-Demand Presentation |
Javid Moslehi, MD |
||
| 9:10 AM (EDT) 15:05 (CEST) |
5 mins | ** Longitudinal antibody Levels and T- cell Response Following BNT162b mRNA Covid19 Vaccine in Patients with Chronic Lymphocytic Leukemia. on Behalf of the Israeli CLL Study Group (1083588) |
Tamar Tadmor, MD |
| 9:15 AM (EDT) 15:15 (CEST) |
5 mins | **Humoral response to mRNA vaccines BNT162b2 and mRNA-1273 COVID-19 in chronic lymphocytic leukemia patients (1084475) |
Cristina Bagacean, MD, PhD |
| 9:20 AM (EDT) 15:20 (CEST) |
35 mins | Panel Discussion featuring the following on-demand presentations: *Infection Risk in CLL *Infection Risk with Novel Agents *COVID-19 and CLL *Management of Autoimmune Cytopenias in the Era of Targeted Agents *Management of Cardiac Complications of BTK Inhibitors |
Jennifer Brown, MD, PhD; Jackie Barrientos, MD; Carsten Niemann, MD, PhD; Florence Cymbalista, MD, PhD; Kerry Rogers, MD; Lydia Scarfò, MD; Javid Moslehi, MD |
| 9:55 AM (EDT) 15:55 (CEST) |
60 mins | Industry Supported Symposia | |
| 10:55 AM (EDT) 16:55 (CEST) |
5 mins | Visit Exhibit Hall & Break | |
| Theme 4: From Global Perspectives to Patient Experiences – How iwCLL Is Leading the Way |
|||
| 11:00 AM (EDT) 17:00 (CEST) |
5 mins | Session 11: Real-World Data and Patient Experiences |
Co-chairs: Peter Hillmen, MB ChB, PhD; John Seymour, MD |
| 11:05 AM (EDT) 17:10 (CEST) |
10 mins | The iwCLL Global Partnerships Sub-Committee Update |
Anna Schuh, MD, PhD |
| 11:15 AM (EDT) 17:15 (CEST) |
7 mins | ERIC Updates |
Paolo Ghia, MD, PhD |
| 11:22 AM (EDT) 17:22 (CEST) |
7 mins | Update on Geographic Diversity and Management of CLL in China |
Shenmiao Yang, MD |
| 11:29 AM (EDT) 17:29 (CEST) |
7 mins | Update on Geographic Diversity and Management of CLL in South America |
Carlos Sergio Chiattone, MD, MSc, PhD |
| 11:36 AM (EDT) 17:36 (CEST) |
7 mins | Update on Geographic Diversity and Management of CLL in Africa |
Clara Chamba, MD |
| 11:43 AM (EDT) 17:43 (CEST) |
5 mins | **Comparison of Clinical and Laboratory Features, Drug Availability, and Outcomes of CLL Patients Treated in Public or in Private Hospitals in Brazil: A Retrospective Analysis of the Brazilian Registry of CLL (1083568) |
Verena Pfister |
| 11:48 AM (EDT) 17:48 (CEST) |
5 mins | **Differences in Availability of Targeted Inhibitors and Use of Chemoimmunotherapy in the First – Line Therapy of Chronic Lymphocytic Leukemia. a European Survey (1083141) |
Lukáš Smolej, MD, PhD |
| 11:53 AM (EDT) 17:53 (CEST) |
15 mins | Real-World Data Roundtable Discussion |
Peter Hillmen, MB ChB, PhD Anna Schuh, MD Paolo Ghia, MD, PhD Shenmiao Yang, MD Carlos Sergio Chiattone, MD, MSc, PhD Clara Chamba, MD |
| 12:08 PM (EDT) 18:08 (CEST) |
7 mins | Visit Exhibit Hall & Break | |
| 12:15 PM (EDT) 18:15 (CEST) |
Session 11: Real-World Data and Patient Experiences (Part 2) |
||
| 12:15 PM (EDT) 18:15 (CEST) |
45 mins | Live Panel Discussion: Spotlight on the CLL Patient Experience: Perspectives Learned From Three Datasets & Patient Experience/Perspective/Solutions |
John Seymour, MD; Deborah Sims; Dr. Brian Koffman, CMO and EVP, CLL Society; Lorna Warwick, CEO, Lymphoma Coalition; Zack Pemberton-Whiteley, CEO, Leukaemia Care |
| 1:00 PM (EDT) 19:00 (CEST) |
5 mins | Session 12: Looking to the Future of CLL and iwCLL | Michael Hallek, MD, PhD; Peter Hillmen, MB ChB, PhD |
| 1:05 PM (EDT) 19:05 (CEST) |
30 mins | Keynote: Advances in CLL: Is It Time to Talk Cure? |
Michael Hallek, MD, PhD |
| 1:35 PM (EDT) 19:35 (CEST) |
15 mins | iwCLL Updates and iwCLL 2023 |
Peter Hillmen, MB ChB, PhD; Jennifer Brown, MD, PhD |
| 1:50 PM (EDT) 19:50 (CEST) |
5 mins | Closing Comments |
Michael Hallek, MD, PhD |
| 1:55 PM (EDT) 19:55 (CEST) |
Close of Workshop |